NASDAQ : ADPT
Adaptive Biotechnologies Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 26.64 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 4.25B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 4.00B |
| Enterprise Value | 4.04B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 159.60M |
| Shares Outstanding | 159.60M |
| Shares Change (YoY) | +4.11% |
| Shares Change (QoQ) | +2.79% |
| Owned by Insiders (%) | 2.58% |
| Owned by Institutions (%) | 80.25% |
| Float | 125.49M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.98 |
| Forward PS | 12.53 |
| PB Ratio | 27.89 |
| P/TBV Ratio | 173.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 13.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.79 |
| Quick Ratio | 4.51 |
| Debt / Equity | 2.72 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.26 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -38.76% |
| Return on Assets (ROA) | -4.12% |
| Return on Invested Capital (ROIC) | -4.88% |
| Return on Capital Employed (ROCE) | -6.77% |
| Weighted Average Cost of Capital (WACC) | 14.80% |
| Revenue Per Employee | $493,720 |
| Profits Per Employee | -$102,330 |
| Employee Count | 624 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 17.30 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.15 |
| 52-Week Price Change | +44.36% |
| 50-Day Moving Average | 26.36 |
| 200-Day Moving Average | 19.64 |
| Relative Strength Index (RSI) | 44.38 |
| Average Volume (20 Days) | 2,050,399 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 11.99M |
| Short Previous Month | 11.84M |
| Short % of Shares Out | 7.51% |
| Short % of Float | 9.56% |
| Short Ratio (days to cover) | 4.56 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 308.08M |
| Gross Profit | 144.62M |
| Operating Income | -37.46M |
| Pretax Income | -63.99M |
| Net Income | -63.85M |
| EBITDA | -21.33M |
| EBIT | -37.46M |
| Loss Per Share | -$0.41 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 344.26M |
| Total Debt | 410.50M |
| Net Cash | -38.76M |
| Net Cash Per Share | -$0.24 |
| Equity (Book Value) | 150.66M |
| Book Value Per Share | 0.90 |
| Working Capital | 332.85M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -21.01M |
| Capital Expenditures | -3.03M |
| Depreciation & Amortization | 16.13M |
| Net Borrowing | 187.41M |
| Free Cash Flow | -24.03M |
| FCF Per Share | -$0.15 |
Margins
| Measure | Value |
|---|
| Gross Margin | 46.94% |
| Operating Margin | -12.16% |
| Pretax Margin | -20.77% |
| Profit Margin | -20.73% |
| EBITDA Margin | -6.92% |
| EBIT Margin | -12.16% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.11% |
| Shareholder Yield | -4.11% |
| Earnings Yield | -1.64% |
| FCF Yield | -0.60% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $30.21 |
| Price Target Difference | 20.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 17.24% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.62 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |